Skip to main content
. Author manuscript; available in PMC: 2020 Apr 20.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2018 Apr 27;45(4):557–575. doi: 10.1007/s10928-018-9585-x

Fig. 3.

Fig. 3

Hepatic TAT mRNA (left panel), TAT protein (center panel), and TAT activity (right panel) dynamics after 50 mg/kg MPL. The circles and bars are means + 1 SD and solid lines depict model (Fig. 1) fitting results based on the parameters shown in Tables 1 and 2